Delivery Order SPE2DB22D1106-SPE2DB25FFFD3
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 120 tablets of Abiraterone Acetate 250 mg, valued at $13,450.30, with an ultimate completion date of July 31, 2025. This competitive award, issued as a firm fixed-price delivery order, is being performed at the contractor's facility in Conshohocken, Pennsylvania. No set-aside designation was used for this procurement. This delivery order is a child contract issued under AmerisourceBergen Drug Corp's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Abiraterone Acetate 500 mg tablets (60-count units) with a ceiling value of $15,739.23. The contract is a firm fixed price delivery order with an ultimate completion date of August 18, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation and represents a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Abiraterone Acetate 500 mg tablets (60-count) with a ceiling value of $8,006.80. This is a firm fixed-price delivery order with an ultimate completion date of August 5, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor that serves as a critical vendor for federal medical procurement needs across military...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Abiraterone Acetate 250 mg tablets (120-count) with a ceiling value of $25,102.49. This competitively awarded, firm fixed-price delivery order is scheduled for completion by July 28, 2025, with performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract utilizes no set-aside designation and represents a pediatric delivery against AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Abiraterone Acetate 500 mg tablets (60-count units) with a ceiling value of $41.4K. This competitive, non-set-aside contract utilizes firm fixed pricing and maintains an ultimate completion date of July 22, 2025. The order will be fulfilled from AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- The Defense Logistics Agency awarded a delivery order valued at $10,774.15 to AmerisourceBergen Drug Corp for the supply of Abiroterone Acetate 250 mg tablets (120 count) on July 21, 2025, with completion scheduled for July 22, 2025. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award to the pharmaceutical distributor. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, performed the work at its corporate office location....
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Abiroterone Acetate 250 mg tablets (120-count) with a contract value of $28,842.31. This competitively awarded, firm fixed-price delivery order is classified as non-set-aside and is scheduled for completion by August 26, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $96,898.94 to AmerisourceBergen Drug Corp for the supply of Abiroterone Acetate 250 mg tablets (120-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 22, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $13,023.83 on July 28, 2025, for the supply of Abiroterone Acetate 500 mg tablets (60-count units). This is a firm fixed-price, non-set-aside contract with performance completion targeted for July 29, 2025, and fulfillment occurring at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Abiroterone Acetate is a hormone therapy medication commonly used in cancer treatment, reflecting the Defense...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,822.78 firm fixed price delivery order is for the supply of 4565133468 Abiraterone Acetate 250 mg tablets. The contract has a ceiling value of $1,822.78 and a completion date of July 15, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FFFD3Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $104,283.60 to AmerisourceBergen Drug Corp for the supply of Abiraterone Acetate 250 mg tablets (120-count units). This competitively awarded, firm fixed-price contract was executed on August 25, 2025, with an ultimate completion date of August 26, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. No set-aside designation was applied to this award. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and active through December 2026. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen Drug Corp supplies a broad range of medications and medical supplies to support military healthcare programs and other government healthcare systems. Abiraterone Acetate is a hormone therapy medication commonly used in oncology treatment, reflecting the contractor's role in providing specialized pharmaceutical commodities across multiple therapeutic domains to the Defense Health Agency and related federal healthcare customers.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $104.3k | 8/25/25 |